However, in a more recent study, SEMA3A was highly enriched in GBM compared to non-neoplastic brain tissues, and function-blocking antibodies against SEMA3A have been developed and successfully tested for inhibition of tumor growth (Lee et al., 2018), suggesting that SEMA3A can also act as a promoter of tumor progression depending on the tissue context. The gene discussed is SEMA3A; the disease is neoplasm.